Skip to content

Activating regulatory intelligence with AI

April 28, 2026

3:00 PM GMT / 10:00 AM EST

Virtual

Regulatory Intelligence Forum about how teams are increasingly using AI to turn insight into confident action. As regulatory teams face growing pressure in 2026 to apply AI more effectively, many are still working through how to do this with confidence and control. Our latest Regulatory Forum brings together Jill Lee from Novo Nordisk and other industry leaders to share how they’re approaching AI use in practice, building accountability, and supporting coordinated action.

Infodesk logo

Applying AI without losing accountability

Across life sciences, regulatory teams are under pressure to use AI more effectively, without compromising diligence or defensibility. Monitoring alone is no longer enough. What matters is how intelligence is curated, assessed, and translated into action across the regulatory value chain.

Based on findings from an Infodesk 2025 customer survey, this Regulatory Forum explores how teams involved in regulatory intelligence, regulatory affairs, quality assurance, GxP, and pharmacovigilance are approaching AI use to strengthen performance in 2026.

This is a peer-led discussion focused on practical approaches, real constraints, and informed caution.

Team of professionals talking in an office and looking at a laptop

What the forum will explore

  • How AI is being adopted across regulatory intelligence and the wider regulatory ecosystem.
  • How regulators and authorities themselves are using AI and what that means for industry.
  • Practical AI use cases across monitoring, curation, refinement, and downstream activation.
  • How teams are approaching AI skills development, including prompt writing and agent-based tools.
  • Where AI adds value today, and where human judgment is still required.
Smilling woman in an office

Forum hosts

Jill Lee

Senior Director, Regulatory Policy at Novo Nordisk and Author at MOSAIC.

Jill is an experienced regulatory policy leader and has been actively involved in discussions and events related to FDA pharmaceutical regulation. She has been selected for the Financial Times’ Agenda Future 50, a list of influential individuals shaping the future of business and society, and is actively involved in cross-industry regulatory initiatives, including work with the AFDO/RAPS Healthcare Products Collaborative.

Corina Posey

Leader in Global Quality Compliance at Vertex Pharmaceuticals

Corina is a quality systems leader with Vertex, a global leader in developing transformative therapies for people with serious diseases. She is responsible for ensuring that products meet the highest standards of safety, efficacy, and compliance with regulatory requirements. Corina has over twenty years’ experience in the pharmaceutical industry with an MBA in Health Care Administration.

Team of professionals working together

Who should take part

This forum is relevant to professionals involved in regulatory decision-making and downstream impact across life sciences, including:

  • Regulatory intelligence and regulatory affairs teams
  • Quality assurance and GxP functions
  • Pharmacovigilance teams
  • Anyone responsible for assessing regulatory impact and coordinating downstream action
Man and woman smiling at a laptop

What you’ll take away

By the end of the session, you’ll leave with a clearer view of how peers are:

  • Using AI with more confidence and control.
  • Embedding intelligence into real workflows, not side tools.
  • Balancing efficiency with defensibility and audit readiness.
  • Identifying practical next steps for 2026, grounded in real experience.

You’ll also be invited to complete a short self-assessment after the event, designed to help regulatory teams understand where they stand today and what actions could strengthen their approach. The assessment generates a free report with a clear summary of findings and recommended actions.

Previous forums

See insights from previous regulatory forums